Merck envisions billions from COVID-19 treatment sales

Merck Results

Merck fell out of the race to develop COVID-19 vaccines earlier this year but could vault to head of the pack for treatments in 2022.

The drugmaker’s potential antiviral, molnupiravir, may generate $5 billion to $7 billion in sales through next year, company executives told analysts Thursday morning. That could include as much as $1 billion this year if regulators authorize it in December.

The company has asked for authorization in both the U.S. and Europe for what would be the first pill to treat COVID-19. All other treatments backed by the U.S. Food and Drug Administration require an IV or injection.

“The need for additional treatment options remains key in combating the COVID-19

pandemic,” Dr. Dean Li, president of Merck research laboratories, told analysts during a Thursday call to discuss third-quarter results.

The FDA has said a panel of outside experts will meet late next month to consider the treatment for use in adults with mild to moderate COVID-19 who are at risk for severe disease or hospitalization.

Merck reported earlier this month that, in testing, the pill cut hospitalizations and deaths by half among patients with early symptoms of COVID-19.

Li said the treatment, which Merck developed with Ridgeback Biotherapeutics, was consistently effective against several virus variants, including the now dominant delta version.

Merck also is studying molnupiravir to see whether it can be used to prevent the spread of COVID-19 in households after someone is exposed to the virus. The company expects results from that research next spring.